Reduction of factor XI levels in TKA patients safe and effective for VTE prevention .
This report has been verified
by one or more authors of the
original publication.
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Factor XI antisense oligonucleotide for prevention of venous thrombosis
N Engl J Med. 2015 Jan 15;372(3):232-40.300 patients scheduled for total knee arthroplasty (TKA) were randomized to receive Factor XI Antisense Oligonucleotide (FXI-ASO) 200 mg, FXI-ASO 300 mg, or enoxaparin 40 mg. This was done to evaluate the safety and efficacy of FXI-ASO in the reduction of risk of venous thromboembolism (VTE) in patients following surgery. Patient outcomes were measured through venography at day 10 +/- 2, to determine the presence of VTE, and through the occurrence of clinically relevant bleeding. Results indicated that patients taking a high dose of FXI-ASO had a decreased incidence of VTE, as well as a decrease in bleeding events following TKA, when compared to patients taking enoxaparin.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
